8-K: T2 Biosystems to be Delisted from Nasdaq, Shifts to OTC Markets

T2 Biosystems faces delisting from the Nasdaq Stock Market due to non-compliance with listing rules and will transition to the OTC Markets system.

Summary

• T2 Biosystems received notification from Nasdaq on February 10, 2025, that its common stock will be delisted.
• Trading of T2 Biosystems' common stock will be suspended on Nasdaq at the open of trading on February 12, 2025.
• The delisting is due to the company's failure to meet the minimum bid price and market value of listed securities requirements.
• T2 Biosystems does not plan to appeal the delisting decision.
• The company's common stock is expected to begin trading on the OTC Markets system under the ticker symbol TTOO on February 12, 2025.
• T2 Biosystems intends to apply for quotation of its common stock on the OTCQX market.
• The company will continue to file periodic reports with the SEC.
• There is no assurance that the company's common stock will continue to trade on the OTC market or that sufficient trading volume will exist.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting from Nasdaq, which raises concerns about the company's financial health and future prospects.

Positives

• T2 Biosystems plans to continue trading on the OTC Markets system.
• The company intends to apply for quotation on the OTCQX market.
• T2 Biosystems will continue to file required periodic reports with the SEC.

Negatives

• T2 Biosystems is being delisted from the Nasdaq Stock Market.
• The company failed to meet the minimum bid price and market value of listed securities requirements.
• There is no guarantee that the company's common stock will continue to trade on the OTC market or that sufficient trading volume will exist.

Risks

• Trading on the OTC Markets system or the OTCQX Market carries potential risks, including liquidity constraints and limited regulatory oversight.
• The company's business operations could be negatively impacted by the delisting.
• The company's common stock may not continue to trade on the OTC market.
• There may not be sufficient trading volume to provide for an efficient trading market.

Future Outlook

The company's future is uncertain, particularly regarding its ability to maintain trading on the OTC market and the potential impact on its business operations.

Industry Context

Delisting from a major exchange like Nasdaq can significantly impact a company's visibility, investor confidence, and access to capital. Companies that are delisted often face increased scrutiny and may struggle to maintain their market value.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the delisting.
• Employees may face uncertainty regarding the company's future.
• The company's ability to raise capital may be limited.

Next Steps

• T2 Biosystems will transition its stock to the OTC Markets system.
• The company plans to submit an application to the OTCQX for quotation of its common stock.
• T2 Biosystems will continue to file its required periodic reports and other filings with the SEC.

Key Dates

Keywords

delisting, Nasdaq, OTC Markets, OTCQX, T2 Biosystems, TTOO, common stock, listing rules, SEC filings